Veteran Ophthalmology Scribes Larry Haimovitch of Haimovitch Medical Technology Consultants and Mike Lachman of EyeQ Research put down the pens and pick up the Mics to share their insights on ophthalmology. ...
Keyword: Regulation
Lifitegrast Heads Up Promising Dry Eye Pipeline
For more than a decade, there has only been one approved pharmacologic treatment for dry eye—Allergan’s Restasis (topical cyclosporine 0.05%). This in a market estimated to be worth more than $2.4 billion, one that ...
Alphaeon’s Grant Explains Innovative New Model
Alphaeon is tapping physicians for unprecedented involvement in finding and funding new treatments. Hear how the company sees the future of health care. ...
How to Do M&A Well
Highlights of a discussion between the ophthalmology sector’s top execs about how to do M&A right. Moderator: Jim Mazzo Jim Mazzo is the Executive Chairman and CEO for AcuFocus. AcuFocus specializes in ...
IOPtima
Ronen Castro, CEO of Israeli company IOPtima Ltd., introduced the CLASS (CO2 Laser-Assisted Sclerectomy Surgery) procedure for glaucoma, which has results comparable to trabeculectomy, but is non-invasive. This was the ...
Alcon’s Head Jeff George Lays Out Vision
Jeff George, President & Global Head of Alcon, shares his optimism for the ophthalmology sector with attendees at the recent Ophthalmology Innovation Summit in Chicago. George explained where Alcon was putting research ...
Anido Guides Aerie’s Push To Be A “Very Big Player” In Glaucoma
Vicente Anido, Jr., PhD’s career has taken him through large companies and private start-ups. He’s taken life science companies public on two occasions, and he’s seen nearly every perspective of the ophthalmology ...
Ophthalmology Leaders Speak to Strength of Sector
A Wall Street Journal analysis of venture capital commitments showed ophthalmology remained the strongest sector within healthcare. According to the Wall Street Journal, privately held ophthalmology start-ups drew ...
The Role of OUS Clinical Studies
Malvina B. Eydelman, MD give her presentation on some of the newest directions coming out of the FDA for device studies in the US followed by a panel discussion on clinical studies in the US vs. clinical studies ...
Cross Linking Market Overview
Presenter: Stephen Slade, MD Stephen Glenn Slade graduated from the University of Texas (Summa Cum Laude, Phi Beta Kappa) with a final, elective year spent at Guy’s Hospital in London. He completed a residency ...
Neovista – A Challenging Journey
Versant Ventures Managing Director William J. Link PhD talks about the journey of NeoVista through all of its ups and downs. Ultimately Neovista was able to get its CE Mark, but failed to get approved by the FDA due to a ...
Cross Linking – Panel Discussion
Moderators: Stephen Slade, MD Stephen Glenn Slade graduated from the University of Texas (Summa Cum Laude, Phi Beta Kappa) with a final, elective year spent at Guy’s Hospital in London. He completed a residency ...
